Genetic Analysis of PHACE Syndrome (Hemangioma With Other Congenital Anomalies)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2013 by Medical College of Wisconsin
Sponsor:
Information provided by (Responsible Party):
Dawn Siegel, Medical College of Wisconsin
ClinicalTrials.gov Identifier:
NCT01016756
First received: November 18, 2009
Last updated: October 31, 2013
Last verified: October 2013
  Purpose
  1. PHACE syndrome(OMIM database number 606519) is the association of a vascular birthmark (hemangioma) on the face along with one or more of the following conditions: congenital heart defects, congenital anomalies of the cerebral arteries,brain, eyes, or sternum.
  2. A research study is currently being conducted at the Medical College of Wisconsin (MCW) to investigate if there is an inherited cause of PHACE syndrome.
  3. We are hoping that this study will lead to a better understanding of how and why children develop PHACE syndrome.

Condition
PHACE Syndrome

Study Type: Observational
Study Design: Observational Model: Family-Based
Time Perspective: Prospective
Official Title: Genetic Analysis of PHACE Syndrome.(PHACE Syndrome is Defined as a Hemangioma Plus One or More of the Following: Brain, Heart, Eye, Sternal or Cerebral Artery Anomalies).

Resource links provided by NLM:


Further study details as provided by Medical College of Wisconsin:

Primary Outcome Measures:
  • Establish a DNA and tissue bank. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Determine candidate genes for PHACE syndrome using a genome-wide approach. [ Time Frame: 10 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Blood (4 ml) for lymphocyte cell lines and DNA and tissue collection from tissue that would otherwise be discarded after surgery.


Estimated Enrollment: 600
Study Start Date: February 2007
Estimated Study Completion Date: January 2017
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Detailed Description:

If you and your child agree to participate in this study, the following will happen:

  1. The principal investigator at MCW, or her appointed representative, will review the study protocol and consent form with you and answer any questions- this can be done over the phone.
  2. If you choose to participate, the investigator will obtain informed consent for study participation, consent to obtain medical records, and a small amount of logistical information such as address and phone number.
  3. Subjects and parents will have a blood draw which can be done a local laboratory.
  4. If the subject undergoes surgery for another reason and there is tissue which would otherwise be discarded, we may ask to receive this sample for research purposes.
  5. We will request completion of surveys about the individual's medical history as it relates to this condition.
  6. The purpose of this study is to promote the understanding of the inheritance of hemangiomas associated with brain, eye and heart anomalies. The DNA obtained from participants are stored in a DNA repository and genetic data bank for current and future research projects related to their genetic disorders. The DNA specimens will be used to map disease-related genes. The principal investigator uses her discretion to decide which investigators will have access to this resource. The analysis of the specimens will vary depending on the investigator and his/her specific protocol.
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Individuals with a facial hemangioma, along with one or more of the following:

posterior fossa malformation, arterial anomalies, cardiac defects, eye anomalies and sternal anomalies.

Criteria

Inclusion Criteria:

  • meets the clinical diagnostic criteria for PHACE syndrome.

Exclusion Criteria:

  • fails to meet the clinical diagnostic criteria for PHACE syndrome.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01016756

Locations
United States, Wisconsin
Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Dawn Siegel, MD    414-955-2819    dsiegel@mcw.edu   
Contact: Shawna Joachim    414-955-2817    sjoachim@mcw.edu   
Principal Investigator: Dawn Siegel, MD         
Sponsors and Collaborators
Medical College of Wisconsin
Investigators
Principal Investigator: Dawn Siegel, MD Medical College of Wisconsin
  More Information

Publications:
Responsible Party: Dawn Siegel, Assistant Professor, Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT01016756     History of Changes
Other Study ID Numbers: PHACE_GENETICS
Study First Received: November 18, 2009
Last Updated: October 31, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Medical College of Wisconsin:
PHACE syndrome
Hemangioma
Coarctation of aorta
Dandy Walker
Brain malformation
Eye anomaly
Sternal malformation
Genetic analysis
Cerebral artery anomaly

Additional relevant MeSH terms:
Hemangioma
Neoplasms, Vascular Tissue
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on August 19, 2014